We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) announced that the FDA has approved Tauvid (flortaucipir F 18 injection), a radioactive diagnostic agent to image tau neurofibrillary tangles (NFTs) in the brain, for helping evaluate patients suspected of being affected by Alzheimer's disease (AD).
Following this nod, the product became the first and the only approved diagnostic agent to image tau NFTs in the brain.
Per the company, the availability of Tauvid will be limited initially and expand in response to commercial demand and payor reimbursement.
Lilly’s wholly owned subsidiary Avid Radiopharmaceuticals developed Tauvid and Amyvid (florbetapir F 18 injection), which demonstrate the presence of one of the two pathologies, beta-amyloid neuritic plaques and tau NFTs, to enable doctors to evaluate AD patients with cognitive impairment. Until now, anatomic distribution and density of tau NFTs in the brain can be determined only at the time of an autopsy of a dead person.
Notably, Tauvid was evaluated in two clinical studies. Both study 1 and study 2 met the respective pre-specified success criteria.
Shares of Lilly have rallied 14.7% so far this year against the industry’s decrease 1.7%.
We note that Alzheimer's is a fatal condition that causes progressive decline in memory. So, it has always been a highly challenging area and not much progress has been made despite significant investments (both funds and resources). There is no medicine available to slow down the progression of this deadly disease. Several companies including Lilly, Biogen (BIIB - Free Report) , Merck (MRK - Free Report) and Roche (RHHBY - Free Report) failed to develop safe and effective treatment options for this deadly brain disease.
Despite the setbacks, companies continue to invest heavily in developing AD treatments, given the high commercial potential in its market. Therefore, availability of an effective diagnostic agent as Tauvid, which can demonstrate NFTs in the brain may aid doctors to accurately diagnose patients and more comprehensively evaluate them.
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
Eli Lilly and Company (LLY - Free Report) announced that the FDA has approved Tauvid (flortaucipir F 18 injection), a radioactive diagnostic agent to image tau neurofibrillary tangles (NFTs) in the brain, for helping evaluate patients suspected of being affected by Alzheimer's disease (AD).
Following this nod, the product became the first and the only approved diagnostic agent to image tau NFTs in the brain.
Per the company, the availability of Tauvid will be limited initially and expand in response to commercial demand and payor reimbursement.
Lilly’s wholly owned subsidiary Avid Radiopharmaceuticals developed Tauvid and Amyvid (florbetapir F 18 injection), which demonstrate the presence of one of the two pathologies, beta-amyloid neuritic plaques and tau NFTs, to enable doctors to evaluate AD patients with cognitive impairment. Until now, anatomic distribution and density of tau NFTs in the brain can be determined only at the time of an autopsy of a dead person.
Notably, Tauvid was evaluated in two clinical studies. Both study 1 and study 2 met the respective pre-specified success criteria.
Shares of Lilly have rallied 14.7% so far this year against the industry’s decrease 1.7%.
We note that Alzheimer's is a fatal condition that causes progressive decline in memory. So, it has always been a highly challenging area and not much progress has been made despite significant investments (both funds and resources). There is no medicine available to slow down the progression of this deadly disease. Several companies including Lilly, Biogen (BIIB - Free Report) , Merck (MRK - Free Report) and Roche (RHHBY - Free Report) failed to develop safe and effective treatment options for this deadly brain disease.
Despite the setbacks, companies continue to invest heavily in developing AD treatments, given the high commercial potential in its market. Therefore, availability of an effective diagnostic agent as Tauvid, which can demonstrate NFTs in the brain may aid doctors to accurately diagnose patients and more comprehensively evaluate them.
Zacks Rank
Lilly currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>